Evotec Announces Progress in Preclinical Neuroscience Partnership with Bristol Myers Squibb
Evotec (NASDAQ: EVO) announced receipt of US$25 million from Bristol Myers Squibb (NYSE: BMY) on October 27, 2025 to support scientific progress in their strategic neuroscience partnership.
The collaboration, launched in 2016 and extended in 2023 for an additional eight years, focuses on discovering disease‑modifying treatments for neurodegenerative diseases. The joint pipeline includes EVT8683 (in‑licensed by BMS in 2021 as BMS‑986419), which has completed Phase 1 clinical trials. Evotec said the payment will advance further research and the partners' joint programs toward potential therapeutic options for patients with neurodegenerative conditions.
Evotec (NASDAQ: EVO) ha annunciato di aver ricevuto 25 milioni di dollari statunitensi da Bristol Myers Squibb (NYSE: BMY) il 27 ottobre 2025 per sostenere i progressi scientifici nella loro partnership strategica nel campo della neuroscienza.
La collaborazione, avviata nel 2016 e estesa nel 2023 per ulteriori otto anni, si concentra sulla scoperta di trattamenti che modificano la malattia per le malattie neurodegenerative. Il portafoglio congiunto comprende EVT8683 (concesso in licenza da BMS nel 2021 come BMS-986419), che ha completato lo studio di Fase 1. Evotec ha riferito che il pagamento avanzerà ulteriori ricerche e i programmi congiunti dei partner verso potenziali opzioni terapeutiche per i pazienti con condizioni neurodegenerative.
Evotec (NASDAQ: EVO) anunció la recepción de US$25 millones de Bristol Myers Squibb (NYSE: BMY) el 27 de octubre de 2025 para apoyar el progreso científico en su asociación estratégica de neurociencia.
La colaboración, iniciada en 2016 y ampliada en 2023 por otros ocho años, se centra en descubrir tratamientos que modifiquen la enfermedad para las enfermedades neurodegenerativas. La cartera conjunta incluye EVT8683 (licenciado por BMS en 2021 como BMS-986419), que ha completado ensayos clínicos de Fase 1. Evotec dijo que el pago impulsará investigaciones adicionales y los programas conjuntos de los socios hacia posibles opciones terapéuticas para pacientes con condiciones neurodegenerativas.
Evotec (NASDAQ: EVO) 는 2025년 10월 27일 Bristol Myers Squibb(NYSE: BMY) 로부터 미화 2,500만 달러를 받아 기초 과학 연구 진전을 지원했다고 발표했다. 이는 전략적 신경과학 파트너십의 일환이다.
2016년에 시작되어 2023년에 추가 8년으로 확장된 이 협력은 신경퇴행성 질환을 위한 질병 변형 치료제 발견에 중점을 두고 있다. 공동 파이프라인에는 2021년 BMS가 BMS-986419로 라이선스한 EVT8683이 포함되며, 1상 임상시험을 완료했다. Evotec은 이 지불이 추가 연구와 양측 파트너의 공동 프로그램을 신경퇴행성 질환 환자들을 위한 잠재적 치료 옵션으로 나아가게 할 것이라고 말했다.
Evotec (NASDAQ: EVO) a annoncé avoir reçu 25 millions de dollars américains de Bristol Myers Squibb (NYSE: BMY) le 27 octobre 2025 pour soutenir les progrès scientifiques dans leur partenariat stratégique en neurosciences.
La collaboration, lancée en 2016 et prolongée en 2023 pour huit années supplémentaires, se concentre sur la découverte de traitements qui modifient l’évolution des maladies pour les maladies neurodégénératives. Le portefeuille conjoint comprend EVT8683 (concédé sous licence par BMS en 2021 sous le nom BMS-986419), qui a terminé des essais cliniques de Phase 1. Evotec a déclaré que le paiement fera progresser davantage la recherche et les programmes conjoints des partenaires vers d’éventuelles options thérapeutiques pour les patients atteints de maladies neurodégénératives.
Evotec (NASDAQ: EVO) gab am 27. Oktober 2025 bekannt, von Bristol Myers Squibb (NYSE: BMY) US$25 Millionen erhalten zu haben, um den wissenschaftlichen Fortschritt in ihrer strategischen Partnerschaft im Bereich Neurowissenschaften zu unterstützen.
Die Zusammenarbeit, die 2016 begann und 2023 für weitere acht Jahre verlängert wurde, konzentriert sich darauf, krankheitsverändernde Behandlungen für neurodegenerative Erkrankungen zu entdecken. Die gemeinsame Pipeline umfasst EVT8683 ( 2021 von BMS unter dem Namen BMS-986419 lizenziert), das eine Phase-1-Studie abgeschlossen hat. Evotec sagte, die Zahlung werde weitere Forschungen und die gemeinsamen Programme der Partner in Richtung potenzieller therapeutischer Optionen für Patienten mit neurodegenerativen Erkrankungen voranbringen.
إيفوتيك (ناسداك: EVO) أعلنت عن تلقي 25 مليون دولار أميركي من Bristol Myers Squibb (NYSE: BMY) في 27 أكتوبر 2025 لدعم التقدم العلمي في شراكتهم الاستراتيجية في مجال علوم الأعصاب.
تم إطلاق التعاون في عام 2016 وتم تمديده في عام 2023 لمدة ثمانية أعوام إضافية، ويركز على اكتشاف علاجات تُغير مسار المرض لأمراض التنكس العصبي. يشمل خط الأنابيب المشترك EVT8683 (مرخصة من BMS في 2021 باسم BMS-986419)، وقد أكمل تجارب المرحلة الأولى. قالت Evotec إن الدفع سيعجل المزيد من البحث والبرامج المشتركة للشركاء نحو خيارات علاجية محتملة للمرضى المصابين بحالات تنكسية عصبية.
Evotec (NASDAQ: EVO) 宣布于 2025年10月27日 收到 Bristol Myers Squibb (NYSE: BMY) 支付的 2500万美元，用于支持其战略神经科学伙伴关系中的科学进展。
该合作自2016年启动，并在 2023 年扩展为另外八年，重点在于为神经退行性疾病发现可改变疾病进程的治疗方法。联合管线包括 EVT8683（在2021年被BMS以BMS-986419许可），已完成 I 期临床试验。 Evotec 表示，该支付将推进进一步的研究与双方的联合项目，朝着为神经退行性疾病患者提供潜在治疗选项的方向发展。
- US$25 million payment received to fund joint neuroscience programs
- Partnership extended in 2023 for an additional 8 years, indicating long‑term collaboration
- EVT8683 (BMS‑986419) completed Phase 1 clinical trials
- Most programs described remain preclinical or early‑stage, limiting near‑term commercial impact
- No efficacy or Phase 2+ clinical data reported for EVT8683 in this announcement
Advances made in preclinical pipeline addressing neurodegenerative diseases
Evotec receives US
$ 25 m payment to support continued progression of joint programs
HAMBURG, DE / ACCESS Newswire / October 27, 2025 / Evotec SE (Frankfurt Stock Exchange: EVT, SDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) today announced that the Company has received a payment of US
Launched in 2016, the collaboration focuses on discovering and developing disease-modifying treatments for neurodegenerative diseases, where current treatment options remain limited. Since then, the companies have built a strong pipeline of innovative programs, including EVT8683, in-licensed by Bristol Myers Squibb in 2021 as BMS-986419, that has completed Phase 1 clinical trials. The partnership was extended in 2023 for an additional eight years, reflecting the shared commitment to bringing transformative treatments into the clinic.
Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Patients living with neurodegenerative conditions urgently need therapies that go beyond the management of symptoms. This achievement increases the depth of our collaboration with Bristol Myers Squibb. Together, we are translating emerging disease biology into potential therapeutic opportunities, with the goal of providing meaningful new options for patients suffering from neurodegenerative diseases."
About Evotec SE
Evotec is a life science company that is pioneering the future of drug discovery and development. By integrating breakthrough science with AI-driven innovation and advanced technologies, we accelerate the journey from concept to cure - faster, smarter, and with greater precision.
Our expertise spans small molecules, biologics, cell therapies and associated modalities, supported by proprietary platforms such as Molecular Patient Databases, PanOmics and iPSC-based disease modeling.
With flexible partnering models tailored to our customers' needs, we work with all Top 20 Pharma companies, over 800 biotechs, academic institutions, and healthcare stakeholders. Our offerings range from standalone services to fully integrated R&D programs and long-term strategic partnerships, combining scientific excellence with operational agility.
Through Just - Evotec Biologics, we redefine biologics development and manufacturing to improve accessibility and affordability.
With a strong portfolio of over 100 proprietary R&D assets, most of them being co-owned, we focus on key therapeutic areas including oncology, cardiovascular and metabolic diseases, neurology, and immunology.
Evotec's global team of more than 4,800 experts operates from sites in Europe and the U.S., offering complementary technologies and services as synergistic centers of excellence. Learn more at www.evotec.com and follow us on LinkedIn and X/Twitter @Evotec .
Forward-looking statements
This announcement contains forward-looking statements concerning future events, including the proposed offering and listing of Evotec's securities. Words such as "anticipate," "believe," "could," "estimate," "expect," "intend," "may," "might," "plan," "potential," "should," "target," "would" and variations of such words and similar expressions are intended to identify forward-looking statements. Such statements include comments regarding Evotec's expectations for revenues, Group EBITDA and unpartnered R&D expenses. These forward-looking statements are based on the information available to, and the expectations and assumptions deemed reasonable by Evotec at the time these statements were made. No assurance can be given that such expectations will prove to have been correct. These statements involve known and unknown risks and are based upon a number of assumptions and estimates, which are inherently subject to significant uncertainties and contingencies, many of which are beyond the control of Evotec. Evotec expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Evotec's expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.
For further information, please contact:
Media
Susanne Kreuter
VP Head of Strategic Marketing
Susanne.Kreuter@evotec.com
Investor Relations
Volker Braun
EVP Head of Global Investor Relations & ESG
Volker.Braun@evotec.com
SOURCE: Evotec SE
View the original press release on ACCESS Newswire
FAQ
How much did Evotec (EVO) receive from Bristol Myers Squibb on October 27, 2025?
What is the purpose of the US$25 million payment to Evotec (EVO)?
Which Evotec program in the collaboration has completed Phase 1 as of October 2025?
When was the Evotec–Bristol Myers Squibb neuroscience partnership extended and for how long?
Does the October 27, 2025 announcement include Phase 2 or efficacy results for Evotec programs?
What diseases does the Evotec–Bristol Myers Squibb partnership target and how might that affect EVO investors?
